CD8A and glioblastoma: The murine variant of this construct–M002–has been well characterized by Parker et al. [53]: In vitro data support its toxicity against human glioblastoma and murine neuroblastoma cell lines, and in vivo survival data from neuroblastoma-bearing mice indicate a significant increase of median survival compared to control; immunohistologic workups of murine brain sections revealed an increase of CD4+- and CD8+-T-cells.